The effect of sodium-glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM. - Guo R; Pandey A; Chandramouli C; Wu MZ; Cai AP; Liu YX; Ren QW; Huang JY; Zhang JN; Gu WL; Xuan HC; Ouwerkerk W; et al. (Diabetes, obesity & metabolism, 2025)